Please Wait...

Bioclinica Medical Imaging Achieves Milestone with Celebration of Primary Endpoint Data Analysis Contributions to 200 FDA Approvals

November 14, 2019

PRINCETON, N.J., November 14, 2019 – Bioclinica Medical Imaging, the world leader in centralized imaging services for clinical trials, announced today that it has reached a milestone in the company’s history: the company has contributed reliable data to the primary efficacy endpoint in more than 200 regulatory submissions from biopharmaceutical clients for therapies and indications subsequently approved by the U.S. Food and Drug Administration.

“At Bioclinica, we are proud to have played a part in helping our clients assess the safety and efficacy of new treatments that improve people’s lives,” said David Herron, President & CEO of Bioclinica. “We are grateful to our scientific and project teams, and to all the patients and their families who participated in the clinical studies.”

Bioclinica provides science and technology expertise to assist the life science industry in advancing the development of medical therapies through services in Medical Imaging, Drug Safety Solutions, and Software Solutions. Bioclinica Medical Imaging provides comprehensive support across multiple therapeutic areas, with particular expertise in oncology, musculoskeletal, cardiovascular, gastrointestinal, neuroscience, endocrinology, infectious and respiratory disease.

“Every day, Bioclinica’s team of professionals works to ensure the quality and integrity of the data we process, ensuring that our clients and regulatory authorities have information they can rely upon to evaluate the safety and efficacy of investigational treatments,” said Todd Kisner, Senior Vice President, Quality Assurance & Regulatory Compliance. “We look forward to continuing to partner with the biopharmaceutical industry as the pace of innovation accelerates and the demand for high-quality image and clinical data analysis combined with regulatory expertise increases.”

 

About Bioclinica

Bioclinica is an integrated clinical life science solutions provider, delivering powerful insight into clinical trial development, assuring greater client success in bringing medical therapies to market, for people around the world. Through deep medical, scientific and technology expertise, the company provides medical imaging and cardiac safety services; clinical adjudication; randomization and trial supply management and optimization; electronic and eSource data capture; site and patient payments; clinical trial management software; and drug safety solutions. Bioclinica’s global team of life science experts serve more than 500 pharmaceutical, biotechnology and device organizations – including the top 20 biopharmaceutical companies and leading CROs – through offices in North America, Europe, and Asia.

 

###

 

Media Contact
Nicole Klatsky
+1 (609) 865-5212

Learn more about Bioclinica at www.Bioclinica.com and in the Bioclinica Blog. Follow the latest company news and happenings on LinkedIn and Twitter.

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

With many clinical trials slowed or terminated, investments in new technologies are difficult. Yet, a #CTMS with a… https://t.co/VRIhWWf4tE
Bioclinica (2 weeks ago)
With Bioclinica #CTMS, sponsors & CROs have access to a full-featured, scalable system - a single, centralized sour… https://t.co/7ACrv8cvuF
Bioclinica (2 weeks ago)
Now available: a DIY #EDC solution. From study start-up to close-out, Bioclinica EDC Solo is an efficient, cost-eff… https://t.co/vFhC7ITfZV
Bioclinica (3 weeks ago)
Reduce the number of user requirement iterations and UAT findings during the #IRT build process. With the agile app… https://t.co/TJt2sZlrFP
Bioclinica (3 weeks ago)
Don't compromise with manual systems and spreadsheets. As an entry-level system with phased implementation, Bioclin… https://t.co/qIpi1MESXw
Bioclinica (4 weeks ago)
According to our recent poll, 45% of respondents had neither a #CTMS nor an #eTMF system, while only 24% had both.… https://t.co/l4dKC7pBQo
Bioclinica (4 weeks ago)